Empagliflozin and Dapagliflozin Outcomes in Heart Failure.

ABSTRACT:

Importance

Sodium-glucose cotransporter-2 inhibitors have emerged as important therapeutic options for heart failure (HF). However, their comparative clinical effectiveness remains uncertain.

Objective

To compare the outcomes associated with dapagliflozin and empagliflozin use in patients diagnosed with HF.

Design, setting, and participants

This cohort study used a clinical data warehouse platform shared by 8 medical centers affiliated with The Catholic University of Korea to screen all patients who were diagnosed with HF between January 2021 and November 2023 at these 8 medical centers. Patients were taking either dapagliflozin or empagliflozin and underwent transthoracic echocardiography. One-to-one propensity score matching was performed to ensure comparable baseli

SUBMITTER: Bu S 

PROVIDER: S-EPMC12679325 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature